{"success":true,"data":{"pressRelease":{"id":"34888","rtpr_id":"nGNX7XjQsy","ticker":"PRE","exchange":"NASDAQ","all_tickers":["PRE"],"title":"Prenetics Announces Preliminary Record Q1 2026 Results with IM8 Revenue Growing Nearly 6x YoY; Company Raises Full-Year 2026 IM8 Revenue Guidance to $190M–$210M","author":"Globe Newswire","published_at":"2026-05-14T12:00:04.650Z","article_body":"* Prenetics records Q1 2026 revenue of $36.0 million with IM8 revenue of\n$33.8 million, up 23.1% from IM8 revenue of $27.4 million in Q4 2025\n* Raises full-year 2026 IM8 revenue guidance to $190 million to $210 million\n(previously $180 million to $200 million)\n* Company projects Q2 2026 revenue of $46 million to $48 million, with IM8\ncontributing $44 million to $46 million, representing approximately 33%\nsequential quarterly growth for IM8\n* IM8 announces the launch of 3 new SKUs in Q4 with Hydration, Creatine and\nKids’ Gummies\n* Prenetics divests full stake of digital assets for $41.3 million in\nproceeds, further boosting its cash balance\n* Prenetics executed approximately $19 million of previously announced $40\nmillion share buyback program\n* Appointed consumer supplements finance veteran Brian J. Rosin as Chief\nFinancial Officer of IM8\n* Company to host earnings call on May 14, 2026, at 8:30 a.m. ET and latest\ninvestor deck can be found at https://ir.prenetics.com\nNEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:\nPRE) (\"Prenetics\" or the \"Company\"), a leading consumer health sciences\ncompany and parent of the IM8 premium health and longevity brand, today\nannounced preliminary financial results for the first quarter ended March 31,\n2026.\n\nThe Company is furnishing preliminary operating results to provide investors\nwith a timely update on IM8’s continued momentum and Prenetics’ strategic\ntransformation, while the Company completes its customary quarter-end closing\nprocedures and related review processes. These procedures include valuation\nworkstreams principally related to non-cash fair-value measurements associated\nwith the Europa 3PL business disposal-related consideration and outstanding\nwarrants. Following completion of these procedures, the Company expects to\nprovide full financial results for the first quarter ended March 31, 2026.\n\nUpon the completion of its customary quarter-end closing procedures and\nrelated review processes, the Company expects to report revenue of $36.0\nmillion, gross profit of $23.3 million, loss from operations of $8.9 million,\nand adjusted EBITDA loss of $5.6 million for the first quarter ended March 31,\n2026.\n\nPreliminary Operating Results\n\n                        Three Months Ended (Unaudited)                                               \n                        March 31, 2026                      March 31, 2025         % Change          \n                        (in million of U.S. dollars)                                                 \n Continuing operations                                                                               \n Revenue                $      36.0                         $      8.3             334.5%            \n Gross profit                  23.3                                5.6             315.2%            \n Loss from operations          (8.9           )                    (6.0   )        48.5%             \n EBITDA (1)                    (26.2) - (4.2  )                    (10.7  )        145.1% - (60.3)%  \n Adjusted EBITDA (2)           (5.6           )                    (4.5   )        23.8%             \n                                                                                                     \n\nThe below tables set out our revenue and gross profit by business unit for the\nfirst quarters ended March 31, 2026 and March 31, 2025.\n\n_____________________________\n(1) EBITDA is a non-IFRS financial measure used by us to measure the strength\nof our core financial and operating performance. EBITDA excludes (1)\ndepreciation and amortization, (2) interest income, (3) other finance costs,\nand (4) income tax expense. For more information regarding this non-IFRS\nfinancial measure, see \"Unaudited Non-IFRS Financial Measures.\"\n(2) Adjusted EBITDA is a non-IFRS financial measure used by us to measure the\nstrength of our core financial and operating performance. Adjusted EBITDA\nrepresents EBITDA further adjusted to exclude (1) equity-settled share-based\npayment expenses, (2) non-recurring expenses related to acquisition, disposal\nand fundraising, (3) strategic realignment and discontinued products impact,\n(4) exchange gain or loss, net, (5) fair value loss on financial assets at\nfair value through profit or loss, (6) fair value loss/(gain) on warrant\nliabilities, (7) unrealized fair value loss on digital asset, (8) share of\nloss of equity-accounted investees, net of tax, (9) gain on disposal of an\nequity-accounted investee, and (10) profit from discontinued operations, net\nof tax. These adjustments are made for items that may not be indicative of our\nbusiness performance, including non-cash and/or non-recurring items. For more\ninformation regarding this non-IFRS financial measure, see \"Unaudited Non-IFRS\nFinancial Measures.\"\n\n                        Three Months Ended (Unaudited)                                 \n                        March 31, 2026                                                 \n                        Revenue                 Gross profit             Gross margin  \n                        (in million of U.S. dollars)                                   \n Continuing operations                                                                 \n CircleDNA              $       2.2             $        1.6             71.6%         \n IM8                            33.8                     21.7            64.3%         \n                        $       36.0            $        23.3            64.8%         \n\n\n\n                        Three Months Ended (Unaudited)                                 \n                        March 31, 2025                                                 \n                        Revenue                 Gross profit             Gross margin  \n                        (in million of U.S. dollars)                                   \n Continuing operations                                                                 \n CircleDNA              $       2.5             $        2.2             86.2%         \n IM8                            5.7                      3.4             59.6%         \n                        $       8.3             $        5.6             67.8%         \n                                                                                       \n\nIM8: A Breakout Global Brand\n\nIM8 continued to demonstrate strong global product-market fit and brand\nmomentum, with Q1 2026 revenue of approximately $33.8 million. Momentum has\naccelerated into the second quarter: IM8 monthly revenue for April 2026\nreached approximately $14.0 million, representing approximately 18.6%\nmonth-over-month growth, and is tracking to reach approximately $15.5 million\nin May 2026, implying annualized recurring revenue(3) of approximately $186\nmillion.\n\nIM8 – Key Performance Indicators\n\n Metric                                        Q1 2026             Q4 2025             Growth      \n Monthly Revenue (End of Period)               $11.8 million       $10.0 million       +18%        \n Quarterly Revenue                             $33.8 million       $27.4 million       +23%        \n Total Customer Orders                         220,000+            230,000+            (4)%        \n Total Servings Delivered                      8.8 million+        6.9 million+        +28%        \n New Customer Average Order Value              $240                $157                +53%        \n Average Order Value (Last Month of Period)    $159                $133                +20%        \n New Customer Subscription Rate                ~79%                ~80%                Maintained  \n Gross Margin                                  ~64%                ~60%                +4%         \n                                                                                                   \n\nIM8 delivered meaningful gross margin expansion in Q1 2026, improving from\napproximately 60% in Q4 2025 to approximately 64% in Q1 2026, an approximately\n400 basis point increase quarter-over-quarter. The improvement was driven by a\ncombination of scale-driven manufacturing efficiencies as production volumes\nincreased across the Daily Ultimate Essentials Pro and Daily Ultimate\nLongevity lines, renegotiated unit economics with key contract manufacturers\nand ingredient suppliers, a favorable product mix shift toward higher-margin\nSKUs and subscription orders, packaging optimization, and improved fulfillment\nand freight efficiencies as order density grew across our 43 international\nmarkets. We expect to maintain gross margin efficiencies through the balance\nof 2026 as volumes scale further and supply chain initiatives mature.\n\nTotal servings delivered grew approximately 28% quarter-over-quarter to over\n8.8 million, reflecting accelerating consumer engagement and increased product\nconsumption across IM8’s global customer base. Total customer orders\ndeclined modestly quarter-over-quarter to approximately 220,000, due to\nIM8’s deliberate and strategic transition towards quarterly subscription\nplans, which consolidate three months of customer demand into a single, larger\norder. As a result, average servings per order increased approximately 33% in\nQ1 2026, consistent with broader quarterly plan adoption. The Company\ncontinues to see an increase in average order value as it expands\ninternationally and scales higher-value subscription formats.\n\n_____________________________\n(3) The Company uses annualized recurring revenue (“ARR”) as a key\noperating metric and is calculated by multiplying the monthly revenue from the\nlast month of a given period by 12.\n\nGlobal Diversification of IM8 Revenue\n\nIM8 continues to expand its international reach, and by the end of Q1 2026,\nIM8 shipped to 43 countries, with over 60% of IM8 revenue generated outside\nthe United States. This international momentum provides a strong foundation\nfor continued global expansion in 2026.\n\nTop Five IM8 Markets (Q1 2026)\n\n Market            Q1 2026 IM8 Revenue    % of Total Q1 2026   \n                                          IM8 Revenue          \n United States     $12.8M                 38.7%                \n Canada            $4.5M                  13.7%                \n United Kingdom    $3.2M                  9.8%                 \n Australia         $1.9M                  5.6%                 \n Singapore         $1.4M                  4.2%                 \n                                                               \n\nStrategic Evolution Towards Quarterly Subscriptions – Driving Step-Change in\nAverage Order Value\n\nFollowing the initial rollout of quarterly subscription plans in the United\nStates in Q4 2025, IM8 expanded quarterly subscription availability across\ninternational markets in Q1 2026. This international rollout validated the\nCompany’s strategy to enhance cash flow, increase upfront customer\ncommitment, improve logistics efficiency, and enhance customer lifetime value\nacross a broader global customer base.\n\nThe impact of this transition has been substantial:\n* FY2025 average order value: ~$110\n* Q4 2025 (last month of period) average order value: ~$133\n* Q1 2026 (new customer) average order value: ~$240\nIM8’s (new customer) average order value increased to approximately $240 in\nQ1 2026, compared with approximately $133 in average order value in Q4 2025\n(last month of period) and approximately $110 in average order value for\nFY2025. This improvement reflects the broader adoption of quarterly\nsubscription plans following the international rollout in 2026 Q1, together\nwith continued demand for higher-value product bundles, including the Beckham\nStack.\n\nQuarterly plans represented a meaningful portion of new customer mix in Q1\n2026, with approximately half of Beckham Stack customers and more than\none-third of Daily Ultimate Essentials Pro customers choosing quarterly\nsubscriptions.\n\nQ2 2026 Outlook\n\nBuilding on the momentum demonstrated in Q1 2026 and reflecting preliminary Q2\n2026 performance, the Company currently expects Q2 2026 revenue in the range\nof approximately $46 million to $48 million, with IM8 contributing\napproximately $44 million to $46 million. At the IM8 level, this outlook\nimplies approximately 33% sequential quarterly revenue growth over IM8 revenue\nof approximately $33.8 million in Q1 2026, and at the Company level implies\napproximately 30% sequential quarterly revenue growth over revenue of $36\nmillion in Q1 2026. This outlook is consistent with the Company’s raised\nfull-year 2026 IM8 revenue guidance of $190 million to $210 million.\n\nDanny Yeung, Chief Executive Officer and Co-Founder, commented: “The\nmomentum behind IM8 is extraordinary. Q1 2026 was a defining quarter — IM8\nrevenue grew nearly 6x year-over-year and 23.1% sequentially over Q4 2025, and\nour quarterly subscription strategy delivered a step-change in customer\neconomics. The acceleration has continued into Q2 2026: April delivered\napproximately $14.0 million in IM8 monthly revenue, an 18.6% increase over\nMarch, and IM8 monthly revenue is tracking to reach approximately $15.5\nmillion in May, implying annualized recurring revenue of approximately $186\nmillion.\n\nBased on this trajectory, we currently expect Q2 2026 revenues of\napproximately $46 million to $48 million, with IM8 contributing approximately\n$44 million to $46 million — representing approximately 33% sequential\nquarterly growth in IM8 revenue. We are also raising our full-year 2026 IM8\nrevenue guidance to $190 million to $210 million, from our prior range of $180\nmillion to $200 million. The strength of our underlying unit economics, the\nglobal pull we are seeing from consumers across more than 40 markets, and the\nupside in new marketing channels gives us strong conviction.\n\nLooking ahead, I am especially excited about our product roadmap. In Q4 2026,\nIM8 plans to launch new offerings in three meaningful categories with very\nlarge addressable markets — hydration, creatine and kids’ gummies —\nextending the brand into high-growth segments and giving our global community\nmore ways to make IM8 part of their daily lives. Each of these launches is\ngrounded in the same standard that defines IM8: world-class science, premium\ningredients and genuine consumer demand.\n\nWhat we have built with David Beckham, our elite roster of athlete partners,\nand our world-class scientific advisory board is becoming a category-defining\nglobal health brand. Q1 proved the model. Q2 is proving the acceleration. The\nrest of 2026 will demonstrate the scale of the opportunity ahead.”\n\nA World-Class Roster of Athlete Partners and Equity-Aligned Ambassadors\n\nA defining feature of the IM8 brand is its roster of world-class athlete\npartners, each of whom has a direct equity-based alignment with the\nCompany’s long-term success. Co-founded with David Beckham, IM8 is\nchampioned by World No. 1 tennis player Aryna Sabalenka, Formula 1 driver\nOllie Bearman of Haas F1 Team, and 2x NBA Most Valuable Player Giannis\nAntetokounmpo, each of whom holds equity in Prenetics. Most recently, IM8\nannounced a multi-year strategic partnership with Inter Miami CF, which\nincludes an equity stake for Inter Miami CF in Prenetics, together with name,\nimage and likeness rights with a minimum of 4 Inter Miami CF players,\nincluding Lionel Messi, and the establishment of an IM8 Nutrition Center at\nthe club’s training facility. The Company believes this equity-based\npartnership model creates deeper, longer-term alignment than traditional\nendorsement arrangements, while supporting global brand reach across some of\nthe most engaged sports audiences in the world.\n\nExpanding the IM8 Product Portfolio – New Q4 2026 Launches\n\nIM8 plans to extend its product portfolio in Q4 2026 with new offerings in\nthree meaningful adjacent categories: hydration, creatine and kids' gummies.\nThese categories represent large, fast-growing segments of the global consumer\nhealth market — the global hydration category is approximately $37 billion,\ngrowing 8% annually; the global creatine category is approximately $1.3\nbillion, growing 26% annually; and the global kids' supplements category is\napproximately $3.6 billion, growing 8% annually, according to Grand View\nResearch — and each is a natural extension of IM8's daily nutrition\nplatform. Each launch will adhere to the same standards that define IM8's\nflagship Daily Ultimate Essentials Pro product, including premium ingredient\nquality, science-backed formulation and rigorous third-party testing. The\nCompany believes these launches will broaden IM8's addressable market,\nincrease customer lifetime value through additional household use cases, and\nsupport continued revenue diversification beyond IM8's flagship SKU.\n\nA Strong, Debt-Free Balance Sheet\n\nPrenetics maintained a strong, debt-free balance sheet as of March 31, 2026,\nwith cash and cash equivalents of $56.0 million and no debt. The Company had\nnet current assets of $111.7 million as of March 31, 2026, up from $56.5\nmillion as of December 31, 2025.\n\nPrenetics held digital assets of $34.8 million as of March 31, 2026.\nSubsequent to March 31, 2026, the Company divested its digital asset holdings\nin full, generating cash proceeds of approximately $41.3 million, which have\nbeen received by the Company.\n\nBased on latest available information, as of May 13, 2026, the Company had\nestimated cash balances across its accounts of approximately $91.3 million. In\naddition, the Company held current financial assets measured at fair value\nthrough profit or loss, representing investments in investment funds, of\napproximately $50 million based on latest available valuation, and cash\nconsideration held in escrow, recorded under other receivables, of\napproximately $6.1 million. As of May 13, 2026, the combined total of the\nCompany’s estimated cash balances, current financial assets measured at fair\nvalue through profit or loss, and cash consideration held in escrow, was\napproximately $147 million.\n\nReturning Capital to Shareholders\n\nOn March 6, 2026, the Company announced a $40 million share repurchase\nprogram. From program launch on March 6, 2026 through May 13, 2026, the\nCompany has repurchased 968,349 of its Class A Ordinary Shares in open-market\ntransactions for a total purchase price of approximately $19 million. The\nrepurchase program reflects the Board’s confidence in the long-term value of\nthe Company and complements continued investment in IM8’s growth\ninitiatives. The Company intends to continue executing repurchases under the\nauthorized program in a disciplined manner, subject to market conditions and\napplicable regulatory requirements.\n\nAdvancing Global Nutrition – Partnership with Vitamin Angels\n\nIn April 2026, Prenetics announced a global partnership between IM8 and\nVitamin Angels, a leading global public health nonprofit with a 31-year track\nrecord, a four-star Charity Navigator rating, and the infrastructure to reach\nmore than 74 million women and children annually across 65+ countries. Under\nthe partnership, IM8 has committed to impacting 400,000 pregnant women,\ninfants, and children under five in underserved communities during the first\nyear, with a long-term goal to impact millions of lives through sustained\nfunding and awareness.\n\nThe partnership extends IM8’s mission beyond premium nutrition to address\nmalnutrition among the world’s most vulnerable populations. The Company\nbelieves that meaningful brand impact is inseparable from meaningful social\nimpact, and that scaling clinical-grade nutrition globally and supporting\nuniversal access to essential nutrition are complementary expressions of the\nsame purpose.\n\nStrengthening IM8 Leadership for the Next Phase of Growth\n\nIM8 also strengthened its leadership team with the appointment of Brian J.\nRosin as Chief Financial Officer of IM8. Mr. Rosin is based in the United\nStates and brings significant experience across consumer health, ecommerce\noperations, finance, and strategic execution, having previously served as CFO\nof Wellbeam Consumer Health and NATURELO Premium Supplements. His appointment\nadds dedicated financial and operational leadership to support IM8’s next\nphase of global growth, disciplined execution, and strategic initiatives.\n\nQ1 2026 Earnings Conference Call\n\nThe Company will hold its earnings conference call on May 14, 2026 at 8:30\na.m. Eastern Time to discuss its financial results in further detail. The call\nwill conclude with a Q&A session with analysts.\n\n Date:                   Thursday, May 14, 2026                                                  \n Time:                   8:30 a.m. Eastern Time                                                  \n Dial-in:                1-877-425-9470                                                          \n International Dial-in:  1-201-389-0878                                                          \n Webcast                 https://viavid.webcasts.com/starthere.jsp?ei=1762906&tp_key=0987da3dac  \n                                                                                                 \n\nAn audio replay of the webcast will be available on the Company’s investor\nrelations website at https://ir.prenetics.com/.\n\nAbout Prenetics\nPrenetics (NASDAQ: PRE) is a leading health sciences company dedicated to\nadvancing human health and longevity. The Company’s flagship consumer brand,\nIM8, co-founded with David Beckham and championed by World No. 1 tennis player\nAryna Sabalenka, is redefining the premium daily nutrition category through\nscience-backed formulations and global brand partnerships. Since its launch,\nIM8 has become one of the fastest-growing brands in consumer health, achieving\nan impressive milestone of surpassing $100 million in annualized recurring\nrevenue within just 11 months of operations, and is now sold in more than 40\ncountries worldwide.\n\nAbout IM8\nIM8 is the pinnacle of premium core nutrition, born from a collaboration\nbetween David Beckham as a co-founding partner, and an elite team of\nscientists spanning medical professionals, academia and space science.\nCombining cutting-edge science with nature’s most potent ingredients, IM8\ndelivers a holistic, science-backed approach to health, empowering you to live\nyour most vibrant life. IM8’s flagship product, Daily Ultimate Essentials\nPro, is an all-in-one powder supplement engineered to replace 16 different\nsupplements in a delicious drink and is NSF Certified for Sport, non-GMO,\nvegan, free from common allergens, and contains no artificial flavors, colors\nor sweeteners. IM8 is a subsidiary of Prenetics (NASDAQ: PRE), a leading\nglobal health sciences company dedicated to advancing consumer health. To\nlearn more about IM8, please visit www.IM8health.com.\n\nInvestor Relations Contact\ninvestors@prenetics.com\nPRE@mzgroup.us\n\nAngela Cheung\nInvestor Relations / Corporate Finance\nangela.hm.cheung@prenetics.com\n\nForward-Looking Statements\nThis press release contains forward-looking statements. These statements are\nmade under the “safe harbor” provisions of the U.S. Private Securities\nLitigation Reform Act of 1995. Statements that are not historical facts,\nincluding statements about the Company’s goals, targets, projections,\noutlooks, beliefs, expectations, strategy, plans, objectives of management for\nfuture operations of the Company, and growth opportunities are forward-looking\nstatements. Our guidance reflects management’s current estimates and\nassumptions as of the date of this release, is subject to significant risks\nand uncertainties, and is not a guarantee of future performance. Actual\nresults may differ materially. In some cases, forward-looking statements can\nbe identified by words or phrases such as “may,” “will,” “expect,”\n“anticipate,” “target,” “aim,” “estimate,” “intend,”\n“plan,” “believe,” “potential,” “continue,” “is/are likely\nto,” “guidance,” “outlook,” “forecast,” or other similar\nexpressions. Forward-looking statements are based upon estimates and forecasts\nand reflect the views, assumptions, expectations, and opinions of the Company,\nwhich involve inherent risks and uncertainties, and therefore they should not\nbe relied upon as being necessarily indicative of future results. A number of\nfactors could cause actual results to differ materially from those contained\nin any forward-looking statement, including but not limited to: the Company\nmay not be able to maintain and enhance its IM8 business and brand if it\nsuffers negative publicity or fails to maintain a strong base of engaged\ncustomers and content creators, or otherwise fails to meet customers’\nexpectations; the Company’s ability to further develop and grow its\nbusiness, including new products and services; and its ability to identify and\nexecute on M&A opportunities. In addition to the foregoing factors, you should\nalso carefully consider the other risks and uncertainties described in the\n“Risk Factors” section of the Company’s most recent registration\nstatement and the prospectus therein, and the other documents filed by the\nCompany from time to time with the U.S. Securities and Exchange Commission.\nUnless otherwise specified, all information provided in this press release is\nas of the date of this press release, and the Company does not undertake any\nduty to update such information, except as required under applicable law.\nNothing in this press release constitutes an offer to sell, or the\nsolicitation of an offer to buy, any securities of the Company.\n\nBasis of Presentation\n\nFigures for prior periods have been re-presented in accordance with IFRS 5\nNon-current Assets Held for Sale and Discontinued Operations (“IFRS 5”).\nIn June 2025, the Group determined that ACT Genomics Holdings Company Limited\n(“ACT Genomics”) met the criteria to be classified as held for sale and a\ndiscontinued operation, following the signing of a definitive sale and\npurchase agreement with Delta Electronics, Inc. The divestment of ACT Genomics\nwas completed on October 1, 2025, and its results have been excluded from the\nGroup’s continuing operations thereafter.\n\nThe Group also completed the divestiture of substantially all of the assets of\nits Europa business in January 2026. Accordingly, Europa’s results are\nincluded in the Group’s financial results only up to the date of completion\nof the divestiture and are excluded from the Group’s continuing operations\nthereafter.\n\nIn accordance with IFRS 5, the results of discontinued operations are\npresented separately from the Group’s continuing operations (comprising IM8\nand CircleDNA) in the unaudited consolidated statements of profit or loss and\nother comprehensive income, and comparative figures for those statements have\nbeen re-presented accordingly. The unaudited consolidated statements of\nfinancial position have not been retrospectively reclassified.\n\nUnaudited non-IFRS financial measures have been provided in this press\nrelease. An explanation of these measures is also included below under the\nheading “Unaudited Non-IFRS Financial Measures”.\n\nSelected Preliminary Unaudited Financial Information\n\nThe financial results presented in this press release are preliminary and\nunaudited and remain subject to completion of the Company’s year-end audit\nby an independent registered public accounting firm. The Company expects to\ninclude its audited consolidated financial statements for the year ended\nDecember 31, 2026 in its Annual Report on Form 20-F to be filed with the U.S.\nSecurities and Exchange Commission.\n\nThe Company is furnishing selected preliminary unaudited financial information\nfor the quarter ended March 31, 2026. The selected information is being\nfurnished while the Company completes its customary quarter-end closing\nprocedures and related review processes for certain non-cash fair-value\nmeasurements.\n\nThe remaining procedures principally relate to valuation of warrants\nassociated with the Company’s December 2025 warrant exchange program and\nshare consideration received in connection with the disposal of the Europa 3PL\nbusiness completed in January 2026. The valuation of the share consideration\ninvolves unlisted equity instruments for which there is no quoted market price\nand includes certain contractual milestones and forfeiture conditions. As a\nresult, the related valuation procedures require additional analysis and\nreview.\n\nThese pending valuation workstreams are not expected to materially affect the\nselected operating metrics included in this press release, including revenue,\ngross profit, operating loss, EBITDA and adjusted EBITDA.\n\nThe selected preliminary unaudited financial information furnished in this\npress release does not constitute a complete set of interim financial\nstatements and should not be viewed as a substitute for complete quarterly\nfinancial information.\n\nThe selected preliminary unaudited financial information remains subject to\ncompletion of the Company’s quarter-end closing procedures, management\nreview and other customary review processes. The Company expects to furnish\nadditional quarterly financial information after these processes have been\ncompleted.\n\nUnaudited Non-IFRS Financial Measures\nTo supplement the Company’s consolidated financial statements prepared in\naccordance with IFRS Accounting Standards, the Company is providing the\nfollowing non-IFRS measures: EBITDA and adjusted EBITDA. These non-IFRS\nfinancial measures are not based on any standardized methodology prescribed by\nIFRS Accounting Standards and are not necessarily comparable to\nsimilarly-titled measures presented by other companies. Management believes\nthese non-IFRS financial measures are useful to investors in evaluating the\nCompany’s ongoing operating results and trends.\n\nManagement is excluding from some or all of its non-IFRS results (1)\ndepreciation and amortization, (2) interest income, (3) other finance costs,\n(4) income tax expense, (5) equity-settled share-based payment expenses, (6)\nnon-recurring expenses related to acquisition, disposal and fundraising, (7)\nstrategic realignment and discontinued products impact, (8) exchange gain or\nloss, net, (9) fair value loss on financial assets at fair value through\nprofit or loss, (10) fair value loss/(gain) on warrant liabilities, (11)\nunrealized fair value loss on digital asset, (12) share of loss of\nequity-accounted investees, net of tax, (13) gain on disposal of an\nequity-accounted investee, and (14) profit from discontinued operations, net\nof tax. These adjustments are made for items that may not be indicative of our\nbusiness, results of operations, or outlook, including but not limited to\nnon-cash and/or non-recurring items. These non-IFRS financial measures are\nlimited in value because they exclude certain items that may have a material\nimpact on the reported financial results. Management accounts for this\nlimitation by analyzing results on an IFRS Accounting Standards basis as well\nas a non-IFRS basis, and also by providing IFRS Accounting Standards measures\nin the Company’s public disclosures.\n\nIn addition, other companies, including companies in the same industry, may\nnot use the same non-IFRS measures or may calculate these metrics in a\ndifferent manner than management, or may use other financial measures to\nevaluate their performance, all of which could reduce the usefulness of these\nnon-IFRS measures as comparative measures. Because of these limitations, the\nCompany’s non-IFRS financial measures should not be considered in isolation\nfrom, or as a substitute for, financial information prepared in accordance\nwith IFRS Accounting Standards.\n\nInvestors are encouraged to review the breakdown provided in the non-IFRS\nreconciliation set forth in the below table captioned “Reconciliation of\nloss for the period under IFRS Accounting Standards and adjusted EBITDA\n(Non-IFRS).”\n\nPRENETICS GLOBAL LIMITED\nUnaudited Non-IFRS Financial Measures\n(All amounts in thousands of U.S. dollars (“$”))\n\nReconciliation of loss for the period under IFRS Accounting Standards and\nadjusted EBITDA (Non-IFRS)\n\n                                                                           Three Months Ended March 31, 2026 (Unaudited)                  \n                                                                           Low End                             High End                   \n Loss for the period under IFRS Accounting Standards                       $        (26,176  )                 $        (4,176   )        \n Depreciation and amortization                                                      184                                 184               \n Interest income                                                                    (294     )                          (294     )        \n Other finance costs                                                                10                                  10                \n Income tax expense                                                                 28                                  28                \n EBITDA                                                                             (26,248  )                          (4,248   )        \n Equity-settled share-based payment expenses                                        1,242                               1,242             \n Non-recurring expenses related to acquisition, disposal and fundraising            953                                 953               \n Strategic realignment and discontinued products impact                             1,252                               1,252             \n Exchange gain or loss, net                                                         (71      )                          (71      )        \n Fair value loss on financial assets at fair value through profit or loss           2,050                               50                \n Fair value loss/(gain) on warrant liabilities                                      9,731                               (10,269  )        \n Unrealized fair value loss on digital assets                                       9,830                               9,830             \n Share of loss of equity-accounted investees, net of tax                            164                                 164               \n Gain on disposal of an equity-accounted investee                                   (4,202   )                          (4,202   )        \n Profit from discontinued operations, net of tax                                    (300     )                          (300     )        \n Adjusted EBITDA (Non-IFRS)                                                $        (5,599   )                 $        (5,599   )        \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/106dbe1a-a6e1-49d9-97a2-c5609258bdc7)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX7XjQsy","title":"Prenetics Announces Preliminary Record Q1 2026 Results with IM8 Revenue Growing Nearly 6x YoY; Company Raises Full-Year 2026 IM8 Revenue Guidance to $190M–$210M","author":"Globe Newswire","ticker":"PRE","created":"2026-05-14T12:00:04.650Z","tickers":["PRE"],"exchange":"NASDAQ","article_body":"* Prenetics records Q1 2026 revenue of $36.0 million with IM8 revenue of\n$33.8 million, up 23.1% from IM8 revenue of $27.4 million in Q4 2025\n* Raises full-year 2026 IM8 revenue guidance to $190 million to $210 million\n(previously $180 million to $200 million)\n* Company projects Q2 2026 revenue of $46 million to $48 million, with IM8\ncontributing $44 million to $46 million, representing approximately 33%\nsequential quarterly growth for IM8\n* IM8 announces the launch of 3 new SKUs in Q4 with Hydration, Creatine and\nKids’ Gummies\n* Prenetics divests full stake of digital assets for $41.3 million in\nproceeds, further boosting its cash balance\n* Prenetics executed approximately $19 million of previously announced $40\nmillion share buyback program\n* Appointed consumer supplements finance veteran Brian J. Rosin as Chief\nFinancial Officer of IM8\n* Company to host earnings call on May 14, 2026, at 8:30 a.m. ET and latest\ninvestor deck can be found at https://ir.prenetics.com\nNEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:\nPRE) (\"Prenetics\" or the \"Company\"), a leading consumer health sciences\ncompany and parent of the IM8 premium health and longevity brand, today\nannounced preliminary financial results for the first quarter ended March 31,\n2026.\n\nThe Company is furnishing preliminary operating results to provide investors\nwith a timely update on IM8’s continued momentum and Prenetics’ strategic\ntransformation, while the Company completes its customary quarter-end closing\nprocedures and related review processes. These procedures include valuation\nworkstreams principally related to non-cash fair-value measurements associated\nwith the Europa 3PL business disposal-related consideration and outstanding\nwarrants. Following completion of these procedures, the Company expects to\nprovide full financial results for the first quarter ended March 31, 2026.\n\nUpon the completion of its customary quarter-end closing procedures and\nrelated review processes, the Company expects to report revenue of $36.0\nmillion, gross profit of $23.3 million, loss from operations of $8.9 million,\nand adjusted EBITDA loss of $5.6 million for the first quarter ended March 31,\n2026.\n\nPreliminary Operating Results\n\n                        Three Months Ended (Unaudited)                                               \n                        March 31, 2026                      March 31, 2025         % Change          \n                        (in million of U.S. dollars)                                                 \n Continuing operations                                                                               \n Revenue                $      36.0                         $      8.3             334.5%            \n Gross profit                  23.3                                5.6             315.2%            \n Loss from operations          (8.9           )                    (6.0   )        48.5%             \n EBITDA (1)                    (26.2) - (4.2  )                    (10.7  )        145.1% - (60.3)%  \n Adjusted EBITDA (2)           (5.6           )                    (4.5   )        23.8%             \n                                                                                                     \n\nThe below tables set out our revenue and gross profit by business unit for the\nfirst quarters ended March 31, 2026 and March 31, 2025.\n\n_____________________________\n(1) EBITDA is a non-IFRS financial measure used by us to measure the strength\nof our core financial and operating performance. EBITDA excludes (1)\ndepreciation and amortization, (2) interest income, (3) other finance costs,\nand (4) income tax expense. For more information regarding this non-IFRS\nfinancial measure, see \"Unaudited Non-IFRS Financial Measures.\"\n(2) Adjusted EBITDA is a non-IFRS financial measure used by us to measure the\nstrength of our core financial and operating performance. Adjusted EBITDA\nrepresents EBITDA further adjusted to exclude (1) equity-settled share-based\npayment expenses, (2) non-recurring expenses related to acquisition, disposal\nand fundraising, (3) strategic realignment and discontinued products impact,\n(4) exchange gain or loss, net, (5) fair value loss on financial assets at\nfair value through profit or loss, (6) fair value loss/(gain) on warrant\nliabilities, (7) unrealized fair value loss on digital asset, (8) share of\nloss of equity-accounted investees, net of tax, (9) gain on disposal of an\nequity-accounted investee, and (10) profit from discontinued operations, net\nof tax. These adjustments are made for items that may not be indicative of our\nbusiness performance, including non-cash and/or non-recurring items. For more\ninformation regarding this non-IFRS financial measure, see \"Unaudited Non-IFRS\nFinancial Measures.\"\n\n                        Three Months Ended (Unaudited)                                 \n                        March 31, 2026                                                 \n                        Revenue                 Gross profit             Gross margin  \n                        (in million of U.S. dollars)                                   \n Continuing operations                                                                 \n CircleDNA              $       2.2             $        1.6             71.6%         \n IM8                            33.8                     21.7            64.3%         \n                        $       36.0            $        23.3            64.8%         \n\n\n\n                        Three Months Ended (Unaudited)                                 \n                        March 31, 2025                                                 \n                        Revenue                 Gross profit             Gross margin  \n                        (in million of U.S. dollars)                                   \n Continuing operations                                                                 \n CircleDNA              $       2.5             $        2.2             86.2%         \n IM8                            5.7                      3.4             59.6%         \n                        $       8.3             $        5.6             67.8%         \n                                                                                       \n\nIM8: A Breakout Global Brand\n\nIM8 continued to demonstrate strong global product-market fit and brand\nmomentum, with Q1 2026 revenue of approximately $33.8 million. Momentum has\naccelerated into the second quarter: IM8 monthly revenue for April 2026\nreached approximately $14.0 million, representing approximately 18.6%\nmonth-over-month growth, and is tracking to reach approximately $15.5 million\nin May 2026, implying annualized recurring revenue(3) of approximately $186\nmillion.\n\nIM8 – Key Performance Indicators\n\n Metric                                        Q1 2026             Q4 2025             Growth      \n Monthly Revenue (End of Period)               $11.8 million       $10.0 million       +18%        \n Quarterly Revenue                             $33.8 million       $27.4 million       +23%        \n Total Customer Orders                         220,000+            230,000+            (4)%        \n Total Servings Delivered                      8.8 million+        6.9 million+        +28%        \n New Customer Average Order Value              $240                $157                +53%        \n Average Order Value (Last Month of Period)    $159                $133                +20%        \n New Customer Subscription Rate                ~79%                ~80%                Maintained  \n Gross Margin                                  ~64%                ~60%                +4%         \n                                                                                                   \n\nIM8 delivered meaningful gross margin expansion in Q1 2026, improving from\napproximately 60% in Q4 2025 to approximately 64% in Q1 2026, an approximately\n400 basis point increase quarter-over-quarter. The improvement was driven by a\ncombination of scale-driven manufacturing efficiencies as production volumes\nincreased across the Daily Ultimate Essentials Pro and Daily Ultimate\nLongevity lines, renegotiated unit economics with key contract manufacturers\nand ingredient suppliers, a favorable product mix shift toward higher-margin\nSKUs and subscription orders, packaging optimization, and improved fulfillment\nand freight efficiencies as order density grew across our 43 international\nmarkets. We expect to maintain gross margin efficiencies through the balance\nof 2026 as volumes scale further and supply chain initiatives mature.\n\nTotal servings delivered grew approximately 28% quarter-over-quarter to over\n8.8 million, reflecting accelerating consumer engagement and increased product\nconsumption across IM8’s global customer base. Total customer orders\ndeclined modestly quarter-over-quarter to approximately 220,000, due to\nIM8’s deliberate and strategic transition towards quarterly subscription\nplans, which consolidate three months of customer demand into a single, larger\norder. As a result, average servings per order increased approximately 33% in\nQ1 2026, consistent with broader quarterly plan adoption. The Company\ncontinues to see an increase in average order value as it expands\ninternationally and scales higher-value subscription formats.\n\n_____________________________\n(3) The Company uses annualized recurring revenue (“ARR”) as a key\noperating metric and is calculated by multiplying the monthly revenue from the\nlast month of a given period by 12.\n\nGlobal Diversification of IM8 Revenue\n\nIM8 continues to expand its international reach, and by the end of Q1 2026,\nIM8 shipped to 43 countries, with over 60% of IM8 revenue generated outside\nthe United States. This international momentum provides a strong foundation\nfor continued global expansion in 2026.\n\nTop Five IM8 Markets (Q1 2026)\n\n Market            Q1 2026 IM8 Revenue    % of Total Q1 2026   \n                                          IM8 Revenue          \n United States     $12.8M                 38.7%                \n Canada            $4.5M                  13.7%                \n United Kingdom    $3.2M                  9.8%                 \n Australia         $1.9M                  5.6%                 \n Singapore         $1.4M                  4.2%                 \n                                                               \n\nStrategic Evolution Towards Quarterly Subscriptions – Driving Step-Change in\nAverage Order Value\n\nFollowing the initial rollout of quarterly subscription plans in the United\nStates in Q4 2025, IM8 expanded quarterly subscription availability across\ninternational markets in Q1 2026. This international rollout validated the\nCompany’s strategy to enhance cash flow, increase upfront customer\ncommitment, improve logistics efficiency, and enhance customer lifetime value\nacross a broader global customer base.\n\nThe impact of this transition has been substantial:\n* FY2025 average order value: ~$110\n* Q4 2025 (last month of period) average order value: ~$133\n* Q1 2026 (new customer) average order value: ~$240\nIM8’s (new customer) average order value increased to approximately $240 in\nQ1 2026, compared with approximately $133 in average order value in Q4 2025\n(last month of period) and approximately $110 in average order value for\nFY2025. This improvement reflects the broader adoption of quarterly\nsubscription plans following the international rollout in 2026 Q1, together\nwith continued demand for higher-value product bundles, including the Beckham\nStack.\n\nQuarterly plans represented a meaningful portion of new customer mix in Q1\n2026, with approximately half of Beckham Stack customers and more than\none-third of Daily Ultimate Essentials Pro customers choosing quarterly\nsubscriptions.\n\nQ2 2026 Outlook\n\nBuilding on the momentum demonstrated in Q1 2026 and reflecting preliminary Q2\n2026 performance, the Company currently expects Q2 2026 revenue in the range\nof approximately $46 million to $48 million, with IM8 contributing\napproximately $44 million to $46 million. At the IM8 level, this outlook\nimplies approximately 33% sequential quarterly revenue growth over IM8 revenue\nof approximately $33.8 million in Q1 2026, and at the Company level implies\napproximately 30% sequential quarterly revenue growth over revenue of $36\nmillion in Q1 2026. This outlook is consistent with the Company’s raised\nfull-year 2026 IM8 revenue guidance of $190 million to $210 million.\n\nDanny Yeung, Chief Executive Officer and Co-Founder, commented: “The\nmomentum behind IM8 is extraordinary. Q1 2026 was a defining quarter — IM8\nrevenue grew nearly 6x year-over-year and 23.1% sequentially over Q4 2025, and\nour quarterly subscription strategy delivered a step-change in customer\neconomics. The acceleration has continued into Q2 2026: April delivered\napproximately $14.0 million in IM8 monthly revenue, an 18.6% increase over\nMarch, and IM8 monthly revenue is tracking to reach approximately $15.5\nmillion in May, implying annualized recurring revenue of approximately $186\nmillion.\n\nBased on this trajectory, we currently expect Q2 2026 revenues of\napproximately $46 million to $48 million, with IM8 contributing approximately\n$44 million to $46 million — representing approximately 33% sequential\nquarterly growth in IM8 revenue. We are also raising our full-year 2026 IM8\nrevenue guidance to $190 million to $210 million, from our prior range of $180\nmillion to $200 million. The strength of our underlying unit economics, the\nglobal pull we are seeing from consumers across more than 40 markets, and the\nupside in new marketing channels gives us strong conviction.\n\nLooking ahead, I am especially excited about our product roadmap. In Q4 2026,\nIM8 plans to launch new offerings in three meaningful categories with very\nlarge addressable markets — hydration, creatine and kids’ gummies —\nextending the brand into high-growth segments and giving our global community\nmore ways to make IM8 part of their daily lives. Each of these launches is\ngrounded in the same standard that defines IM8: world-class science, premium\ningredients and genuine consumer demand.\n\nWhat we have built with David Beckham, our elite roster of athlete partners,\nand our world-class scientific advisory board is becoming a category-defining\nglobal health brand. Q1 proved the model. Q2 is proving the acceleration. The\nrest of 2026 will demonstrate the scale of the opportunity ahead.”\n\nA World-Class Roster of Athlete Partners and Equity-Aligned Ambassadors\n\nA defining feature of the IM8 brand is its roster of world-class athlete\npartners, each of whom has a direct equity-based alignment with the\nCompany’s long-term success. Co-founded with David Beckham, IM8 is\nchampioned by World No. 1 tennis player Aryna Sabalenka, Formula 1 driver\nOllie Bearman of Haas F1 Team, and 2x NBA Most Valuable Player Giannis\nAntetokounmpo, each of whom holds equity in Prenetics. Most recently, IM8\nannounced a multi-year strategic partnership with Inter Miami CF, which\nincludes an equity stake for Inter Miami CF in Prenetics, together with name,\nimage and likeness rights with a minimum of 4 Inter Miami CF players,\nincluding Lionel Messi, and the establishment of an IM8 Nutrition Center at\nthe club’s training facility. The Company believes this equity-based\npartnership model creates deeper, longer-term alignment than traditional\nendorsement arrangements, while supporting global brand reach across some of\nthe most engaged sports audiences in the world.\n\nExpanding the IM8 Product Portfolio – New Q4 2026 Launches\n\nIM8 plans to extend its product portfolio in Q4 2026 with new offerings in\nthree meaningful adjacent categories: hydration, creatine and kids' gummies.\nThese categories represent large, fast-growing segments of the global consumer\nhealth market — the global hydration category is approximately $37 billion,\ngrowing 8% annually; the global creatine category is approximately $1.3\nbillion, growing 26% annually; and the global kids' supplements category is\napproximately $3.6 billion, growing 8% annually, according to Grand View\nResearch — and each is a natural extension of IM8's daily nutrition\nplatform. Each launch will adhere to the same standards that define IM8's\nflagship Daily Ultimate Essentials Pro product, including premium ingredient\nquality, science-backed formulation and rigorous third-party testing. The\nCompany believes these launches will broaden IM8's addressable market,\nincrease customer lifetime value through additional household use cases, and\nsupport continued revenue diversification beyond IM8's flagship SKU.\n\nA Strong, Debt-Free Balance Sheet\n\nPrenetics maintained a strong, debt-free balance sheet as of March 31, 2026,\nwith cash and cash equivalents of $56.0 million and no debt. The Company had\nnet current assets of $111.7 million as of March 31, 2026, up from $56.5\nmillion as of December 31, 2025.\n\nPrenetics held digital assets of $34.8 million as of March 31, 2026.\nSubsequent to March 31, 2026, the Company divested its digital asset holdings\nin full, generating cash proceeds of approximately $41.3 million, which have\nbeen received by the Company.\n\nBased on latest available information, as of May 13, 2026, the Company had\nestimated cash balances across its accounts of approximately $91.3 million. In\naddition, the Company held current financial assets measured at fair value\nthrough profit or loss, representing investments in investment funds, of\napproximately $50 million based on latest available valuation, and cash\nconsideration held in escrow, recorded under other receivables, of\napproximately $6.1 million. As of May 13, 2026, the combined total of the\nCompany’s estimated cash balances, current financial assets measured at fair\nvalue through profit or loss, and cash consideration held in escrow, was\napproximately $147 million.\n\nReturning Capital to Shareholders\n\nOn March 6, 2026, the Company announced a $40 million share repurchase\nprogram. From program launch on March 6, 2026 through May 13, 2026, the\nCompany has repurchased 968,349 of its Class A Ordinary Shares in open-market\ntransactions for a total purchase price of approximately $19 million. The\nrepurchase program reflects the Board’s confidence in the long-term value of\nthe Company and complements continued investment in IM8’s growth\ninitiatives. The Company intends to continue executing repurchases under the\nauthorized program in a disciplined manner, subject to market conditions and\napplicable regulatory requirements.\n\nAdvancing Global Nutrition – Partnership with Vitamin Angels\n\nIn April 2026, Prenetics announced a global partnership between IM8 and\nVitamin Angels, a leading global public health nonprofit with a 31-year track\nrecord, a four-star Charity Navigator rating, and the infrastructure to reach\nmore than 74 million women and children annually across 65+ countries. Under\nthe partnership, IM8 has committed to impacting 400,000 pregnant women,\ninfants, and children under five in underserved communities during the first\nyear, with a long-term goal to impact millions of lives through sustained\nfunding and awareness.\n\nThe partnership extends IM8’s mission beyond premium nutrition to address\nmalnutrition among the world’s most vulnerable populations. The Company\nbelieves that meaningful brand impact is inseparable from meaningful social\nimpact, and that scaling clinical-grade nutrition globally and supporting\nuniversal access to essential nutrition are complementary expressions of the\nsame purpose.\n\nStrengthening IM8 Leadership for the Next Phase of Growth\n\nIM8 also strengthened its leadership team with the appointment of Brian J.\nRosin as Chief Financial Officer of IM8. Mr. Rosin is based in the United\nStates and brings significant experience across consumer health, ecommerce\noperations, finance, and strategic execution, having previously served as CFO\nof Wellbeam Consumer Health and NATURELO Premium Supplements. His appointment\nadds dedicated financial and operational leadership to support IM8’s next\nphase of global growth, disciplined execution, and strategic initiatives.\n\nQ1 2026 Earnings Conference Call\n\nThe Company will hold its earnings conference call on May 14, 2026 at 8:30\na.m. Eastern Time to discuss its financial results in further detail. The call\nwill conclude with a Q&A session with analysts.\n\n Date:                   Thursday, May 14, 2026                                                  \n Time:                   8:30 a.m. Eastern Time                                                  \n Dial-in:                1-877-425-9470                                                          \n International Dial-in:  1-201-389-0878                                                          \n Webcast                 https://viavid.webcasts.com/starthere.jsp?ei=1762906&tp_key=0987da3dac  \n                                                                                                 \n\nAn audio replay of the webcast will be available on the Company’s investor\nrelations website at https://ir.prenetics.com/.\n\nAbout Prenetics\nPrenetics (NASDAQ: PRE) is a leading health sciences company dedicated to\nadvancing human health and longevity. The Company’s flagship consumer brand,\nIM8, co-founded with David Beckham and championed by World No. 1 tennis player\nAryna Sabalenka, is redefining the premium daily nutrition category through\nscience-backed formulations and global brand partnerships. Since its launch,\nIM8 has become one of the fastest-growing brands in consumer health, achieving\nan impressive milestone of surpassing $100 million in annualized recurring\nrevenue within just 11 months of operations, and is now sold in more than 40\ncountries worldwide.\n\nAbout IM8\nIM8 is the pinnacle of premium core nutrition, born from a collaboration\nbetween David Beckham as a co-founding partner, and an elite team of\nscientists spanning medical professionals, academia and space science.\nCombining cutting-edge science with nature’s most potent ingredients, IM8\ndelivers a holistic, science-backed approach to health, empowering you to live\nyour most vibrant life. IM8’s flagship product, Daily Ultimate Essentials\nPro, is an all-in-one powder supplement engineered to replace 16 different\nsupplements in a delicious drink and is NSF Certified for Sport, non-GMO,\nvegan, free from common allergens, and contains no artificial flavors, colors\nor sweeteners. IM8 is a subsidiary of Prenetics (NASDAQ: PRE), a leading\nglobal health sciences company dedicated to advancing consumer health. To\nlearn more about IM8, please visit www.IM8health.com.\n\nInvestor Relations Contact\ninvestors@prenetics.com\nPRE@mzgroup.us\n\nAngela Cheung\nInvestor Relations / Corporate Finance\nangela.hm.cheung@prenetics.com\n\nForward-Looking Statements\nThis press release contains forward-looking statements. These statements are\nmade under the “safe harbor” provisions of the U.S. Private Securities\nLitigation Reform Act of 1995. Statements that are not historical facts,\nincluding statements about the Company’s goals, targets, projections,\noutlooks, beliefs, expectations, strategy, plans, objectives of management for\nfuture operations of the Company, and growth opportunities are forward-looking\nstatements. Our guidance reflects management’s current estimates and\nassumptions as of the date of this release, is subject to significant risks\nand uncertainties, and is not a guarantee of future performance. Actual\nresults may differ materially. In some cases, forward-looking statements can\nbe identified by words or phrases such as “may,” “will,” “expect,”\n“anticipate,” “target,” “aim,” “estimate,” “intend,”\n“plan,” “believe,” “potential,” “continue,” “is/are likely\nto,” “guidance,” “outlook,” “forecast,” or other similar\nexpressions. Forward-looking statements are based upon estimates and forecasts\nand reflect the views, assumptions, expectations, and opinions of the Company,\nwhich involve inherent risks and uncertainties, and therefore they should not\nbe relied upon as being necessarily indicative of future results. A number of\nfactors could cause actual results to differ materially from those contained\nin any forward-looking statement, including but not limited to: the Company\nmay not be able to maintain and enhance its IM8 business and brand if it\nsuffers negative publicity or fails to maintain a strong base of engaged\ncustomers and content creators, or otherwise fails to meet customers’\nexpectations; the Company’s ability to further develop and grow its\nbusiness, including new products and services; and its ability to identify and\nexecute on M&A opportunities. In addition to the foregoing factors, you should\nalso carefully consider the other risks and uncertainties described in the\n“Risk Factors” section of the Company’s most recent registration\nstatement and the prospectus therein, and the other documents filed by the\nCompany from time to time with the U.S. Securities and Exchange Commission.\nUnless otherwise specified, all information provided in this press release is\nas of the date of this press release, and the Company does not undertake any\nduty to update such information, except as required under applicable law.\nNothing in this press release constitutes an offer to sell, or the\nsolicitation of an offer to buy, any securities of the Company.\n\nBasis of Presentation\n\nFigures for prior periods have been re-presented in accordance with IFRS 5\nNon-current Assets Held for Sale and Discontinued Operations (“IFRS 5”).\nIn June 2025, the Group determined that ACT Genomics Holdings Company Limited\n(“ACT Genomics”) met the criteria to be classified as held for sale and a\ndiscontinued operation, following the signing of a definitive sale and\npurchase agreement with Delta Electronics, Inc. The divestment of ACT Genomics\nwas completed on October 1, 2025, and its results have been excluded from the\nGroup’s continuing operations thereafter.\n\nThe Group also completed the divestiture of substantially all of the assets of\nits Europa business in January 2026. Accordingly, Europa’s results are\nincluded in the Group’s financial results only up to the date of completion\nof the divestiture and are excluded from the Group’s continuing operations\nthereafter.\n\nIn accordance with IFRS 5, the results of discontinued operations are\npresented separately from the Group’s continuing operations (comprising IM8\nand CircleDNA) in the unaudited consolidated statements of profit or loss and\nother comprehensive income, and comparative figures for those statements have\nbeen re-presented accordingly. The unaudited consolidated statements of\nfinancial position have not been retrospectively reclassified.\n\nUnaudited non-IFRS financial measures have been provided in this press\nrelease. An explanation of these measures is also included below under the\nheading “Unaudited Non-IFRS Financial Measures”.\n\nSelected Preliminary Unaudited Financial Information\n\nThe financial results presented in this press release are preliminary and\nunaudited and remain subject to completion of the Company’s year-end audit\nby an independent registered public accounting firm. The Company expects to\ninclude its audited consolidated financial statements for the year ended\nDecember 31, 2026 in its Annual Report on Form 20-F to be filed with the U.S.\nSecurities and Exchange Commission.\n\nThe Company is furnishing selected preliminary unaudited financial information\nfor the quarter ended March 31, 2026. The selected information is being\nfurnished while the Company completes its customary quarter-end closing\nprocedures and related review processes for certain non-cash fair-value\nmeasurements.\n\nThe remaining procedures principally relate to valuation of warrants\nassociated with the Company’s December 2025 warrant exchange program and\nshare consideration received in connection with the disposal of the Europa 3PL\nbusiness completed in January 2026. The valuation of the share consideration\ninvolves unlisted equity instruments for which there is no quoted market price\nand includes certain contractual milestones and forfeiture conditions. As a\nresult, the related valuation procedures require additional analysis and\nreview.\n\nThese pending valuation workstreams are not expected to materially affect the\nselected operating metrics included in this press release, including revenue,\ngross profit, operating loss, EBITDA and adjusted EBITDA.\n\nThe selected preliminary unaudited financial information furnished in this\npress release does not constitute a complete set of interim financial\nstatements and should not be viewed as a substitute for complete quarterly\nfinancial information.\n\nThe selected preliminary unaudited financial information remains subject to\ncompletion of the Company’s quarter-end closing procedures, management\nreview and other customary review processes. The Company expects to furnish\nadditional quarterly financial information after these processes have been\ncompleted.\n\nUnaudited Non-IFRS Financial Measures\nTo supplement the Company’s consolidated financial statements prepared in\naccordance with IFRS Accounting Standards, the Company is providing the\nfollowing non-IFRS measures: EBITDA and adjusted EBITDA. These non-IFRS\nfinancial measures are not based on any standardized methodology prescribed by\nIFRS Accounting Standards and are not necessarily comparable to\nsimilarly-titled measures presented by other companies. Management believes\nthese non-IFRS financial measures are useful to investors in evaluating the\nCompany’s ongoing operating results and trends.\n\nManagement is excluding from some or all of its non-IFRS results (1)\ndepreciation and amortization, (2) interest income, (3) other finance costs,\n(4) income tax expense, (5) equity-settled share-based payment expenses, (6)\nnon-recurring expenses related to acquisition, disposal and fundraising, (7)\nstrategic realignment and discontinued products impact, (8) exchange gain or\nloss, net, (9) fair value loss on financial assets at fair value through\nprofit or loss, (10) fair value loss/(gain) on warrant liabilities, (11)\nunrealized fair value loss on digital asset, (12) share of loss of\nequity-accounted investees, net of tax, (13) gain on disposal of an\nequity-accounted investee, and (14) profit from discontinued operations, net\nof tax. These adjustments are made for items that may not be indicative of our\nbusiness, results of operations, or outlook, including but not limited to\nnon-cash and/or non-recurring items. These non-IFRS financial measures are\nlimited in value because they exclude certain items that may have a material\nimpact on the reported financial results. Management accounts for this\nlimitation by analyzing results on an IFRS Accounting Standards basis as well\nas a non-IFRS basis, and also by providing IFRS Accounting Standards measures\nin the Company’s public disclosures.\n\nIn addition, other companies, including companies in the same industry, may\nnot use the same non-IFRS measures or may calculate these metrics in a\ndifferent manner than management, or may use other financial measures to\nevaluate their performance, all of which could reduce the usefulness of these\nnon-IFRS measures as comparative measures. Because of these limitations, the\nCompany’s non-IFRS financial measures should not be considered in isolation\nfrom, or as a substitute for, financial information prepared in accordance\nwith IFRS Accounting Standards.\n\nInvestors are encouraged to review the breakdown provided in the non-IFRS\nreconciliation set forth in the below table captioned “Reconciliation of\nloss for the period under IFRS Accounting Standards and adjusted EBITDA\n(Non-IFRS).”\n\nPRENETICS GLOBAL LIMITED\nUnaudited Non-IFRS Financial Measures\n(All amounts in thousands of U.S. dollars (“$”))\n\nReconciliation of loss for the period under IFRS Accounting Standards and\nadjusted EBITDA (Non-IFRS)\n\n                                                                           Three Months Ended March 31, 2026 (Unaudited)                  \n                                                                           Low End                             High End                   \n Loss for the period under IFRS Accounting Standards                       $        (26,176  )                 $        (4,176   )        \n Depreciation and amortization                                                      184                                 184               \n Interest income                                                                    (294     )                          (294     )        \n Other finance costs                                                                10                                  10                \n Income tax expense                                                                 28                                  28                \n EBITDA                                                                             (26,248  )                          (4,248   )        \n Equity-settled share-based payment expenses                                        1,242                               1,242             \n Non-recurring expenses related to acquisition, disposal and fundraising            953                                 953               \n Strategic realignment and discontinued products impact                             1,252                               1,252             \n Exchange gain or loss, net                                                         (71      )                          (71      )        \n Fair value loss on financial assets at fair value through profit or loss           2,050                               50                \n Fair value loss/(gain) on warrant liabilities                                      9,731                               (10,269  )        \n Unrealized fair value loss on digital assets                                       9,830                               9,830             \n Share of loss of equity-accounted investees, net of tax                            164                                 164               \n Gain on disposal of an equity-accounted investee                                   (4,202   )                          (4,202   )        \n Profit from discontinued operations, net of tax                                    (300     )                          (300     )        \n Adjusted EBITDA (Non-IFRS)                                                $        (5,599   )                 $        (5,599   )        \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/106dbe1a-a6e1-49d9-97a2-c5609258bdc7)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-14T12:00:04.724169687Z","server_sent_at_ms":1778760004724},"received_at":"2026-05-14T12:00:04.776Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}